Takeda Pharmaceutical Company Limited American Depositary Shares (Each Representing 1/2 Of A Share Of) (TAK) closed at $20.87 on November 2, 2026, down 0.2% from the previous close, on volume of 2,470,889 shares (30-day average 2,701,595).
Data as of November 2, 2026.
Takeda Earnings Call Highlights Profit Growth and Pipeline Progress
TipRanks (Mon, 2-Nov 7:20 PM ET)
Takeda spotlights ORZEYFUL approvals and raises FY2026 forecast as reported operating profit jumps
Market Chameleon (Fri, 30-Oct 7:53 AM ET)
Takeda Pharmaceutical Non-GAAP EPS of ¥308.00, revenue of ¥2407B; upgrades FY 2026 outlook
Seeking Alpha News (Thu, 29-Oct 2:40 AM ET)
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
Business Wire (Thu, 29-Oct 2:36 AM ET)
Takeda’s Mobocertinib Trial Update: What Lung Cancer Data Mean for TAK Investors
TipRanks (Wed, 28-Oct 12:30 PM ET)
Takeda Pharmaceutical Q2 Earnings Preview
Seeking Alpha News (Wed, 28-Oct 11:02 AM ET)
Business Wire (Fri, 23-Oct 7:30 AM ET)
Business Wire (Mon, 19-Oct 5:30 AM ET)
Business Wire (Wed, 14-Oct 8:30 PM ET)
Business Wire (Wed, 14-Oct 8:00 AM ET)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
Takeda Pharmaceutical Company Limited American Depositary Shares (Each Representing 1/2 Of A Share Of) trades on the NYSE stock market under the symbol TAK.
As of November 2, 2026, TAK stock price declined to $20.87 with 2,470,889 million shares trading.
TAK has a beta of -0.08, meaning it tends to be less sensitive to market movements. TAK has a correlation of 0.00 to the broad based SPY ETF.
TAK has a market cap of $66.65 billion. This is considered a Large Cap stock.
Last quarter Takeda Pharmaceutical Company Limited American Depositary Shares (Each Representing 1/2 Of A Share Of) reported $7 billion in Revenue and $.48 earnings per share. This beat revenue expectation by $267 million and exceeded earnings estimates by $.17.
In the last 3 years, TAK traded as high as $21.22 and as low as $12.58.
The top ETF exchange traded funds that TAK belongs to (by Net Assets): FVD, PPH, AVDE, IDVO, APIE.
TAK has outperformed the market in the last year with a price return of +57.7% while the SPY ETF gained +11.7%. TAK has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +21.0% and +6.1%, respectively, while the SPY returned +1.7% and -1.5%, respectively.
TAK support price is $20.62 and resistance is $21.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TAK shares will trade within this expected range on the day.
